Vitamin C for preventing atrial fibrillation in high risk patients: a systematic review and meta-analysis

Table 1 Characteristics of included trials

Trial (ref.)	Country	Setting	No. of Participants	Mean age (yr)	Proportion males
van Wagoner 2003 [27]	USA	CABG	346	63	NA
Donovan 2012 [30]	USA	CABG or valvular surgery	304	64	76%
Sadeghpour 2015 [31]	Iran	CABG or valvular surgery	290	56	66%
Bjordahl 2012 [18]	USA	CABG	185	63	67%
Papoulidis 2011 [21]	Greece	CABG	170	73	71%
Sarzaeem 2014 [26]	Iran	CABG	170	59	69%
Samadikhah 2014 [25]	Iran	CABG	120	61	68%
Antonic 2016 [23]	Slovenia	CABG	105	64	78%
Dehghani 2014 [19]	Iran	CABG	100	61	74%
Eslami 2007 [20]	Iran	CABG	100	60	67%
Korantzopoulos 2005 [32]	Greece	Cardioversion	44	68	59%
Rebrova 2012 [24]	Russia	CABG	40	59	100%
Healy 2010 [29]	USA	CABG or valvular surgery	30	NA	NA
Colby 2011 [28]	USA	CABG or valvular surgery	24	65	79%
Polymeropoulos 2015 [22]	Greece	CABG	22	70	59%

The trials are listed by the number of patients. The two largest trials [27, 30], both carried out at the USA, have not been published because of their negative findings. For the US trials, the weighted mean age was 63.4 years and for the non-US trials, it was 61.8 years. For the US trials, the overall proportion of males was 73%, and for the non-US trials, it was 70%
CABG Coronary artery bypass grafting, NA Not available

ISSN: 1471-2261